binding affinity News and Research

RSS

Increased transmission in open spike conformations of SARS-CoV-2 variants

Researchers from Yale University and the University of Texas have collaborated to investigate mutations in some VOCs.

14 Oct 2021

New molecular understanding of variations in salmonella virulence

Researchers from the University of Seville, in collaboration with the universities of Zaragoza and Kansas (USA), have managed to describe hitherto unknown processes that allow us to understand the virulence of a Salmonella infection.

11 Oct 2021

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Scientists develop a cell-free assay to screen SARS-CoV-2 entry inhibitors

Scientists have developed and validated a cell-free fluorescence assay for the rapid screening of protein inhibitors.

7 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Researchers published a study on the expression and functional analyses of a neutralizing mAb with identical variable domains but different constant HCs, representing IgG1-4.

6 Oct 2021

What makes SARS-CoV-2 variants more virulent?

Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Novel framework can predict changes that may increase the infectiousness of SARS-CoV-2

As SARS-CoV-2 continues to evolve, new variants are expected to arise that may have an increased ability to infect their hosts and evade the hosts' immune systems.

29 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

A novel protein modeling method assesses changes to the conformation of the SARS-CoV-2 spike protein that have been encountered by mutation.

19 Sep 2021

Development of a potential pan-variant aerosol to manage COVID-19

Researchers hypothesized that if APN01 could be directly introduced into the airways of an infected person, it could locally neutralize SARS-CoV-2.

19 Sep 2021

Therapeutic potential of clinical-grade ACE2 for blocking SARS-CoV-2 variants

According to new research by an international team of scientists, all SARS-CoV-2 variants, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced affinity toward recombinant human soluble ACE2.

16 Sep 2021

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

A recent report published in the journal Cell Discovery has described the immunogenicity and protective efficacy of a novel coronavirus disease 2019 (COVID-19) subunit vaccine candidate. The vaccine induces robust immune responses in rodents and non-human primates and protects the animals against severe disease.

12 Sep 2021

The role of nanobodies in capturing and containing SARS-CoV-2

Scientists have repurposed the Nb Ty1 for the detection and neutralization of SARS-CoV-2.

8 Sep 2021

Is the SARS-CoV-2 Lambda variant more vaccine-resistant than the Delta variant?

Researchers in the USA and China recently published a report in which they discussed the potential factors that confer high infectivity and immune resistance on the Delta and Lambda variants.

6 Sep 2021

Study finds SARS-CoV-2 affects the brain by binding with MAO enzymes

A new study by researchers in Croatia and Slovenia shows the SARS-CoV-2 spike protein has an affinity towards monoamine oxidases (MAO) enzymes. Changes in MAO levels have been the culprit for several neuropsychiatric disorders such as Parkinson’s or Alzheimer’s disease.

6 Sep 2021

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

The emergence of escape mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is somewhat less likely for the Delta variant in comparison with the original or wild type virus, shows a recent study currently available on the bioRxiv* preprint server while it undergoes peer review.

5 Sep 2021

Role of glycans on the SARS-CoV-2 spike protein in human receptor interaction

A team of investigators, led by Dr. Benjamin F. Mann, from Merck, USA have published a new study on the preprint server bioRxiv*. They have used a biochemical approach to control the glycosylation profile of the S protein receptor-binding domain (RBD) and to analyze the effect of different glycosylation patterns on receptor binding.

30 Aug 2021

Could genetic variants in host cell receptors (ACE2) explain COVID-19 susceptibility among certain ethnic groups?

Led by Ioannis Karakikes of Stanford University, a new study suggests some hospitalized patients with COVID-19 contain ACE2 genetic variants that increase ACE2 expression. Some variants that altered ACE2 protein expression and binding affinity were more prevalent in people with European backgrounds.

30 Aug 2021